Tiziana Life Sciences Ltd. (TLSA), a clinical-stage biopharmaceutical company, announced Monday positive six-month clinical results in multiple sclerosis patients treated with intranasal Foralumab.
Alzheimer’s disease (AD) has a new candidate for its treatment. Nasal anti-CD3 monoclonal antibody (MAb) reduced microglia activation in the brain of mice without its effect being dependent on the β-amyloid (Aβ) deposits characteristic of this neurodegenerative disorder. “We have done many basic studies in the laboratory on microglia. Microglia activation occurs in many neurologic diseases. One of them is multiple sclerosis (MS). And it also occurs in AD,” senior author Howard Weiner told BioWorld.
Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple. | June 5, 2023
Results confirm positive signal previously reported in the first two Expanded Access patients who both subsequently demonstrated clinical improvementsPhase.